Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99.8 SEK | +0.81% | +0.40% | +26.97% |
05-08 | Transcript : Devyser Diagnostics AB, Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Devyser Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 1,346 | 1,152 | 1,280 | 1,625 | - | - |
Enterprise Value (EV) 2 | 981 | 810.1 | 1,092 | 1,414 | 1,438 | 1,625 |
P/E ratio | -49.7 x | -24.7 x | -23.9 x | -435 x | 41.5 x | 19.2 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 14.4 x | 9.1 x | 7.56 x | 6.51 x | 4.75 x | 4.38 x |
EV / Revenue | 10.5 x | 6.4 x | 6.45 x | 5.66 x | 4.2 x | 4.38 x |
EV / EBITDA | -64.5 x | -18.7 x | -23.8 x | 137 x | 23.3 x | 16.6 x |
EV / FCF | -53 x | -12.6 x | -10.7 x | -177 x | 95.9 x | 18.9 x |
FCF Yield | -1.89% | -7.95% | -9.32% | -0.57% | 1.04% | 5.29% |
Price to Book | 3.37 x | 2.66 x | 3.35 x | 3.9 x | 3.37 x | - |
Nbr of stocks (in thousands) | 15,188 | 16,006 | 16,284 | 16,284 | - | - |
Reference price 3 | 64.41 | 48.08 | 52.71 | 63.80 | 63.80 | 63.80 |
Announcement Date | 24/02/22 | 21/02/23 | 20/02/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 93.5 | 126.6 | 169.3 | 249.8 | 342.3 | 371.1 |
EBITDA 1 | - | -15.2 | -43.4 | -45.8 | 10.35 | 61.74 | 98 |
EBIT 1 | - | -21.2 | -52 | -58.9 | -1.315 | 45.69 | 76.1 |
Operating Margin | - | -22.67% | -41.07% | -34.79% | -0.53% | 13.35% | 20.51% |
Earnings before Tax (EBT) 1 | - | -21.9 | -52.7 | -54.4 | -0.415 | 45.64 | 71 |
Net income 1 | -10.91 | -20.7 | -46 | -53.6 | -3.355 | 37.58 | 86 |
Net margin | - | -22.14% | -36.33% | -31.66% | -1.34% | 10.98% | 23.17% |
EPS 2 | -0.000920 | -1.297 | -1.949 | -2.205 | -0.1465 | 1.536 | 3.330 |
Free Cash Flow 1 | - | -18.5 | -64.4 | -101.7 | -8 | 15 | 86 |
FCF margin | - | -19.79% | -50.87% | -60.07% | -3.2% | 4.38% | 23.17% |
FCF Conversion (EBITDA) | - | - | - | - | - | 24.3% | 87.76% |
FCF Conversion (Net income) | - | - | - | - | - | 39.91% | 100% |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 11/05/21 | 24/02/22 | 21/02/23 | 20/02/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 24.5 | 30.4 | 30.9 | 31.2 | 34.2 | 39.5 | 37.7 | 46.7 | 45.4 | 50.7 | 53.2 | 58.5 | 62.5 |
EBITDA | - | - | - | - | - | -16.3 | -11.1 | -4.1 | -14.2 | - | - | - | - |
EBIT 1 | -13.9 | -5.2 | -12.6 | -8.2 | -25.9 | -19.1 | -13.5 | -7.8 | -18.5 | -12.2 | -6.9 | -3.2 | -0.5 |
Operating Margin | -56.73% | -17.11% | -40.78% | -26.28% | -75.73% | -48.35% | -35.81% | -16.7% | -40.75% | -24.06% | -12.97% | -5.47% | -0.8% |
Earnings before Tax (EBT) | - | - | - | - | - | -19.3 | -13.8 | -5.2 | -16.2 | - | - | - | - |
Net income | - | - | - | - | - | -19.9 | -14.6 | -6 | -13.1 | - | - | - | - |
Net margin | - | - | - | - | - | -50.38% | -38.73% | -12.85% | -28.85% | - | - | - | - |
EPS | - | - | - | - | - | -0.8259 | -0.5650 | -0.2366 | -0.5328 | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 24/02/22 | 11/05/22 | 24/08/22 | 10/11/22 | 21/02/23 | 09/05/23 | 23/08/23 | 09/11/23 | 20/02/24 | 08/05/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 365 | 342 | 188 | 211 | 187 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -18.5 | -64.4 | -102 | -8 | 15 | 86 |
ROE (net income / shareholders' equity) | - | -7.79% | -10.8% | -13.1% | -0.81% | 8.89% | 21% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | 19.10 | 18.10 | 15.80 | 16.40 | 19.00 | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 2.2 | 7.9 | 11.5 | 8.78 | 8.76 | 13 |
Capex / Sales | - | 2.35% | 6.24% | 6.79% | 3.51% | 2.56% | 3.5% |
Announcement Date | 11/05/21 | 24/02/22 | 21/02/23 | 20/02/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.97% | 148M | |
+17.96% | 47.02B | |
+48.77% | 41.86B | |
+1.17% | 41.76B | |
-4.27% | 28.8B | |
+11.42% | 26.05B | |
-21.39% | 19.15B | |
+4.86% | 12.55B | |
+27.29% | 12.34B | |
-3.50% | 11.82B |
- Stock Market
- Equities
- DVYSR Stock
- Financials Devyser Diagnostics AB